Pain is the prominent feature of sickle cell disease (SCD) and negatively affects quality of life. Delivery of pain management programmes (PMPs) has been suggested in clinical guidelines for pain management in SCD; however, further evidence of the feasibility and effectiveness of PMPs in this population is needed. This study explored the feasibility of delivering a sickle cell pain management programme (SCPMP) for adults within a haemoglobinopathies service.
Methods
A single arm, repeated-measures observational design was used to determine feasibility of delivering the SCPMP at one study site. Primary feasibility outcomes were recruitment, completion of treatment and outcome measures, satisfaction, credibility and acceptability to participants. Secondary feasibility outcomes were treatment outcomes and processes, frequency of vaso-occlusive crisis (VOC) and healthcare utilisation.
Results
Four of five feasibility criteria were met. Annual recruitment of eight participants to a SCPMP was not achieved. Twenty-nine people began a SCPMP during the study period. Twenty-five (86.2%) participants attended ≥5/8 sessions and 21(84%) programme completers provided all end of programme questionnaires. Mean scores of >7 on ten-point scales were seen across satisfaction and credibility questions. At least moderate (Hedges g >0.5) effect sizes were seen in pre-post SCPMP measures of pain interference, anxiety, depression, self-efficacy, pain-related worry and acceptance. A small (Hedges g 0.4) effect size was seen in HRQoL. Following SCPMP attendance, mean frequency of self-reported VOC and hospital admissions reduced.
Conclusions
This study suggests that, given an adequate source of referrals, a SCPMP is feasible to deliver and appears acceptable and credible to participants. Exploration of influences on recruitment, such as barriers to group interventions, would be illuminating, prior to investigating feasibility of an adequately powered randomised-controlled trial.
HollinsMStonerockGLKisaalitaNR, et al.Detecting the emergence of chronic pain in sickle cell disease. J Pain Symptom Manage2012; 43: 1082–1093. DOI: 10.1016/j.jpainsymman.2011.06.020.
SinhaCBBakshiNRossD, et al.Management of chronic pain in adults living with sickle cell disease in the era of the opioid epidemic. JAMA Netw Open2019; 2: e194410. DOI: 10.1001/jamanetworkopen.2019.4410.
5.
SmithWRPenberthyLTBovbjergVE, et al.Daily assessment of pain in adults with sickle cell disease. Ann Intern Med2008; 148: 94–101. DOI: 10.7326/0003-4819-148-2-200801150-00004.
6.
BallasSKDarbariDS. Review/overview of pain in sickle cell disease. Compl Ther Med2020; 49: 102327. DOI: 10.1016/j.ctim.2020.102327.
7.
OsunkwoIO’ConnorHFSaahE. Optimizing the management of chronic pain in sickle cell disease. Hematology Am Soc Hematol Educ Program2020; 2020: 562–569. DOI: 10.1182/hematology.2020000143.
8.
NicholasMVlaeyenJWSRiefW, et al.The IASP classification of chronic pain for ICD-11: chronic primary pain. Pain2019; 160: 28–37. DOI: 10.1097/j.pain.0000000000001390.
9.
DampierCPalermoTMDarbariDS, et al.AAPT Diagnostic criteria for chronic sickle cell disease pain. J Pain2017; 18: 490–498. DOI: 10.1016/j.jpain.2016.12.016.
10.
LevensonJLMcClishDKDahmanBA, et al.Depression and anxiety in adults with sickle cell disease: the PiSCES project. Psychosom Med2008; 70: 192–196. DOI: 10.1097/PSY.0b013e31815ff5c5.
MarmotM. Social determinants of health inequalities. Lancet2005; 365: 1099–1104. DOI: 10.1016/S0140-6736(05)71146-6.
14.
MahaseE. Sickle cell disease: inquiry finds serious care failings and racism towards patients. London: British Medical Journal Publishing Group, 2021.
15.
Thalassemia APPGoSCa. No one’s listening: an inquiry into the avoidable deaths and failures of care for sickle cell patients in secondary care. London, UK: Sickle Cell Society, 2021.
16.
GlassbergJATanabePChowA, et al.Emergency provider analgesic practices and attitudes toward patients with sickle cell disease. Ann Emerg Med2013; 62: 293–302.e210. DOI: 10.1016/j.annemergmed.2013.02.004.
17.
Power-HaysAMcGannPT. When actions speak louder than words — racism and sickle cell disease. N Engl J Med2020; 383: 1902–1903. DOI: 10.1056/nejmp2022125.
18.
WilliamsHTanabeP. Sickle cell disease: a review of nonpharmacological approaches for pain. J Pain Symptom Manage2016; 51: 163–177. DOI: 10.1016/j.jpainsymman.2015.10.017.
19.
Sickle Cell Society. Standards for the clincial care of Adults with Sickle Cell Disease in the UK, 2nd Edition. 2018. United Kingdom: Sickle Cell Society.
20.
BrandowAMCarrollCPCrearyS, et al.American society of hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain. Blood Adv2020; 4: 2656–2701. DOI: 10.1182/bloodadvances.2020001851.
21.
BadawySMAbebeKZReichmanCA, et al.Comparing the effectiveness of education versus digital cognitive behavioral therapy for adults with sickle cell disease: protocol for the cognitive behavioral therapy and real-time pain management intervention for sickle cell via mobile applications (CaRISMA) study. JMIR Res Protoc2021; 10: e29014. DOI: 10.2196/29014.
22.
Society BP. Guidelines for pain management programmes for adults. London, UK: British Pain Society, 2013.
23.
BuscemiVChickenJMahyT, et al.An updated audit of the patient selection process for pain management programmes in a speciality care service before and during the COVID-19 pandemic. Br J Pain2022; 17(3): 226–238. DOI: 10.1177/20494637221147200.
24.
KamperSJApeldoornATChiarottoA, et al. Multidisciplinary biopsychosocial rehabilitation for chronic low back pain. Cochrane Database Syst Rev. 2014; (9): CD000963. doi:10.1002/14651858.CD000963.pub3
25.
WilliamsACCFisherEHearnL, et al.Psychological therapies for the management of chronic pain (excluding headache) in adults. Cochrane Database Syst Rev2020; 8(8): CD007407. DOI: 10.1002/14651858.CD007407.pub4.
26.
McCrackenLMYuLVowlesKE. New generation psychological treatments in chronic pain. BMJ2022; 376: e057212. DOI: 10.1136/bmj-2021-057212.
27.
McCrackenLMVowlesKE. Acceptance and commitment therapy and mindfulness for chronic pain: model, process, and progress. Am Psychol2014; 69: 178–187. DOI: 10.1037/a0035623.
28.
ThornBEKuhajdaMC. Group cognitive therapy for chronic pain. J Clin Psychol2006; 62: 1355–1366. DOI: 10.1002/jclp.20315.
29.
Newton-JohnTRGeddesJ. The non-specific effects of group-based cognitive-behavioural treatment of chronic pain. Chronic Illn2008; 4: 199–208. DOI: 10.1177/1742395308091868.
30.
WilsonDMackintoshSNicholasMK, et al.Are group identity and sense of belonging relevant for group pain management programmes? An exploratory pilot study. Br J Pain2022; 16(5): 528–537. DOI: 10.1177/20494637221098941.
31.
ThomasVNWilson-BarnettJGoodhartF. The role of cognitive-behavioural therapy in the management of pain in patients with sickle cell disease. J Adv Nurs1998; 27: 1002–1009. DOI: 10.1046/j.1365-2648.1998.00584.x.
32.
ThomasVJDixonALMilliganP. Cognitive-behaviour therapy for the management of sickle cell disease pain: an evaluation of a community-based intervention. Br J Health Psychol1999; 4: 209–229.
33.
ThomasV. Cognitive behavioural therapy in pain management for sickle cell disease. Int J Palliat Nurs2000; 6: 434–442. DOI: 10.12968/ijpn.2000.6.9.9055.
34.
AnieKAGreenJ. Psychological therapies for sickle cell disease and pain. Cochrane Database Syst Rev2015; 2015(5): CD001916. DOI: 10.1002/14651858.CD001916.pub3.
35.
CrosbyLEJoffeNEPeughJ, et al.Pilot of the chronic disease self-management program for adolescents and young adults with sickle cell disease. J Adolesc Health2017; 60: 120–123. DOI: 10.1016/j.jadohealth.2016.08.022.
36.
SchatzJSchlenzAMMcClellanCB, et al.Changes in coping, pain, and activity after cognitive-behavioral training. Clin J Pain2015; 31: 536–547. DOI: 10.1097/ajp.0000000000000183.
37.
BarakatLPSchwartzLASalamonKS, et al.A family-based randomized controlled trial of pain intervention for adolescents with sickle cell disease. J Pediatr Hematol Oncol2010; 32: 540–547. DOI: 10.1097/MPH.0b013e3181e793f9.
38.
EldridgeSMChanCLCampbellMJ, et al.CONSORT 2010 statement: extension to randomised pilot and feasibility trials. BMJ2016; 355: i5239. DOI: 10.1136/bmj.i5239.
39.
LancasterGAThabaneL. Guidelines for reporting non-randomised pilot and feasibility studies. Pilot Feasibility Stud2019; 5: 114. DOI: 10.1186/s40814-019-0499-1.
40.
JuliousS. Sample size of 12 per group rule of thumb for pilot study. Pharmaceut Stat2005; 4: 287–291. DOI: 10.1046/j.152-1497.2001.016009606.x.
41.
SimJLewisM. The size of a pilot study for a clinical trial should be calculated in relation to considerations of precision and efficiency. J Clin Epidemiol2012; 65: 301–308. DOI: 10.1016/j.jclinepi.2011.07.011.
DevillyGJBorkovecTD. Psychometric properties of the credibility/expectancy questionnaire. J Behav Ther Exp Psychiatry2000; 31: 73–86. DOI: 10.1016/s0005-7916(00)00012-4.
44.
DeyoRABattieMBeurskensAJ, et al.Outcome measures for low back pain research. A proposal for standardized use. Spine (Phila Pa 1976)1998; 23: 2003–2013. DOI: 10.1097/00007632-199809150-00018.
45.
HurstHBoltonJ. Assessing the clinical significance of change scores recorded on subjective outcome measures. J Manip Physiol Ther2004; 27: 26–35. DOI: 10.1016/j.jmpt.2003.11.003.
46.
DworkinRHTurkDCFarrarJT, et al.Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain2005; 113: 9–19. DOI: 10.1016/j.pain.2004.09.012.
47.
CleelandCSRyanKM. Pain assessment: global use of the brief pain inventory. Ann Acad Med Singap1994; 23: 129–138.
48.
ZigmondASSnaithRP. The hospital anxiety and depression scale. Acta Psychiatr Scand1983; 67: 361–370. DOI: 10.1111/j.1600-0447.1983.tb09716.x.
49.
HerdmanMGudexCLloydA, et al.Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res2011; 20: 1727–1736. DOI: 10.1007/s11136-011-9903-x.
50.
NicholasMK. The pain self-efficacy questionnaire: taking pain into account. Eur J Pain2007; 11: 153–163. DOI: 10.1016/j.ejpain.2005.12.008.
51.
SullivanMJBishopSRPivikJ. The pain catastrophizing scale: development and validation. Psychol Assess1995; 7: 524.
52.
FishRAMcGuireBHoganM, et al.Validation of the chronic pain acceptance questionnaire (CPAQ) in an Internet sample and development and preliminary validation of the CPAQ-8. Pain2010; 149: 435–443. DOI: 10.1016/j.pain.2009.12.016.
53.
WestBTWelchKBGaleckiAT. Linear mixed models: a practical guide using statistical software. Boca Raton, FL: Chapman and Hall/CRC, 2006.
54.
CohenJ. Statistical power analysis for the behavioural sciences. 2nd ed. ed.New York: Routledge, 1988.
55.
FagerlandMWLydersenSLaakeP. The McNemar test for binary matched-pairs data: mid-p and asymptotic are better than exact conditional. BMC Med Res Methodol2013; 13: 1–8.
56.
HairJJrAndersonRTathamR, et al.Multivariate data analysis. 5th ed.Upper Saddle River, NJ: Prentice Hall, 1998.
57.
EfronBTibshiraniRJ. An introduction to the bootstrap. Monogr Stat Appl Probab1993; 57.
58.
BenjaminiYHochbergY. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Stat Soc B1995; 57: 289–300.
59.
WilliamsDBoothGCohenH, et al.Rapid design and implementation of a virtual pain management programme due to COVID-19: a quality improvement initiative. Br J Pain2022; 16: 191–202. DOI: 10.1177/20494637211039252.
60.
EcclestonCBlythFMDearBF, et al.Managing patients with chronic pain during the COVID-19 outbreak: considerations for the rapid introduction of remotely supported (eHealth) pain management services. Pain2020; 161: 889–893. DOI: 10.1097/j.pain.0000000000001885.
61.
OosterhavenJWittinkHMollemaJ, et al.Predictors of dropout in interdisciplinary chronic pain management programmes: a systematic review. J Rehabil Med2019; 51: 2–10. DOI: 10.2340/16501977-2502.
62.
CroninRMHankinsJSByrdJ, et al.Modifying factors of the health belief model associated with missed clinic appointments among individuals with sickle cell disease. Hematology2018; 23: 683–691. DOI: 10.1080/10245332.2018.1457200.
63.
LetzenJEMathurVAJanevicMR, et al.Confronting racism in all forms of pain research: reframing study designs. J Pain2022; 23: 893–912. DOI: 10.1016/j.jpain.2022.01.010.
64.
HoodAMBookerSQMoraisCA, et al.Confronting racism in all forms of pain research: a shared commitment for engagement, diversity, and dissemination. J Pain2022; 23: 913–928. DOI: 10.1016/j.jpain.2022.01.008.
65.
EdwardsRTelfairJCecilH, et al.. Reliability and validity of a self-efficacy instrument specific to sickle cell disease. Behav Res Ther2000; 38: 951–963.
66.
JanevicMRMathurVABookerSQ, et al.Making pain research more inclusive: why and how. J Pain2022; 23: 707–728. DOI: 10.1016/j.jpain.2021.10.004.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
